In a recent webinar, Achieve Data Integrity, Quality & Compliance Across Your Organization, Emerson’s Michalle Adkins and Hilary Mills-Baker share how data integrity means complete, consistent, accurate data throughout its lifecycle.
To know where you’re going, you have to know where you are, and operating a life sciences manufacturing facility is no exception. Pharmaceutical processors regularly have to take stock of their technological capacity to keep a finger on the pulse of the four main...
Emerson’s Michalle Adkins and AspenTech’s Chuck Miller team up to present Robust PAT Solutions to Support Process Development, Tech Transfer and Manufacturing at IFPAC 2023.
Recently, as cell and gene therapies have begun to emerge in the life sciences manufacturing landscape, an important concept has begun to draw attention: traceability. However, it is important to remember that traceability was critical long before today’s most...
People are more aware than ever of the many amazing ways new treatments can improve their lives. As a result, life sciences companies are under more pressure than ever to safely deliver new, innovative treatments to market to satisfy customer demand. The key to...
In just the last 10 years, biopharmaceutical supply chains have changed dramatically. The single-source manufacturing model is becoming much rarer, making way for multi-enterprise manufacturing collaborations and partnerships to better meet the changing needs of the...
There can be little question that Industry 4.0 technologies are reshaping the way life sciences companies operate. In the wake of the rapid development of vaccines during the COVID-19 pandemic, more facilities than ever are being “born digital.” Some of these...
On Monday at the Emerson Exchange Users’ Conference, Emerson’s Michalle Adkins and AbbVie’s Jeff Ziolkowski moderated a panel with Fujifilm’s Soren Skerris, Takeda’s Dr. Nina Schwalb, Eli Lilly’s James Weber, and Emerson’s Christian Berg. The experts shared the...
Traditional manufacturing practices have served the biopharmaceutical industry well for years, but times are changing and a need for speed to market in life sciences while reducing manufacturing costs is putting a focus on enabling real-time release (RTR)....
One of the key stages delaying and increasing costs in life sciences projects is equipment validation. In fact, it is one of the elements of project completion that project teams are most eager to compress because the value of every incremental improvement is so...
In an Australasian BioTechnology article, Facilities for a Strong Future, Emerson’s Michalle Adkins and Makarand Mujumdar share how pharmaceutical and biotech manufacturers can improve local capacity to meet the needs of the regions in which they operate.
As consumers of medicinal products of various kinds (vaccines, immunotherapies, tablets, capsules, cell therapies, etc.), we know that although product quality is important, reliable supply is also critical. A reliable supplier of therapeutic goods requires the...
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to stay up to date on the latest news, events and innovations that will help you face and solve your toughest challenges.
Just post a link to the entry and send us a quick note so we can share your work. Thank you very much.
Our Global Community
Emerson Exchange 365
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.